Journal Articles

Epidemiology and Natural Science

• The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.
  Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. Ann Intern Med. 2012 Feb 21;156(4):271-8.
• Medicine and the epidemic of incarceration in the United States.
  Rich JD, Wakeman SE, Dickman SL. N Engl J Med. 2011 Jun 2;364(22):2081-3.
• The healthcare burden imposed by liver disease in aging Baby Boomers.
  Davis GL, Roberts WL. Curr Gastroenterol Rep. 2010 Feb;12(1):1-6.
• Diagnosis, management, and treatment of hepatitis C: an update.
  Ghany MG, Strader DB, Thomas DL, et al. Hepatology. 2009 Apr;49(4):1335-74.
• A functional genomic screen identifies cellular cofactors of hepatitis C virus replication.
  Tai AW, Benita Y, Peng LF, et al. Cell Host Microbe. 2009 Mar 19;5(3):298-307.
• Elevated prevalence of hepatitis C infection in users of United States veterans medical centers
  Dominitz JA, et al. Hepatology. 2005;41:88-96.
• Hepatitis C tested prevalence and comorbidities among veterans in the US Northwest
  Sloan KL, et al. J Clin Gastroenterol. 2004 Mar;38(3):279-84.
• CDC: Prevalence of hepatitis C virus infection among clients of HIV counseling and testing sites -- Connecticut, 1999
  Morbidity and Mortality Weekly Report, July 13, 2001.
• CDC: Hepatitis C virus infection among firefighters, emergency medical technicians, and paramedics -- selected locations, United States, 1991-2000
  Morbidity and Mortality Weekly Report, July 28, 2000.

Prevention and Transmission

• Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV partners study.
  Terrault NA, Dodge JL, Murphy EL, et al. Hepatology. 2013 Mar;57(3):881-9.
• Transmission of hepatitis C virus infection through tattooing and piercing: a critical review.
  Tohme RA and Holmberg SD. Clin Infect Dis. 2012 Apr;54(8):1167-78. Epub 2012 Jan 30.
• Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008.
  Thompson ND, Perz JF, Moorman AC, Holmberg SD. Ann Intern Med. 2009 Jan 6;150(1):33-9. Review.

Testing and Counseling

• Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945-1965
  Morbidity and Mortality Weekly Report: Recommendations and Reports, August 17, 2012 / 61(RR04);1-18
• ACIP immunization update.
  Campos-Outcalt D. J Fam Pract. 2012 Mar;61(3):150-2.
• The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. Primary care settings.
  Rein DB, Smith BD, Wittenborn JS, et al. Ann Intern Med. 2012 Feb 21;156(4):263-70. Epub 2011 Nov 4.
• Economic model of a birth cohort screening program for hepatitis C virus.
  McGarry LJ, Pawar VS, Parekh HH, et al. Hepatology. 2011 Dec 2. doi: 10.1002/hep.25510. [Epub ahead of print]
• HCV screening practices and prevalence in an MCO, 2000-2007.
  Roblin DW, Smith BD, Weinbaum CM, Sabin ME. Am J Manag Care. 2011;17(8):548-55.
• Molecular diagnostics of hepatitis C virus infection: a systematic review.
  Scott JD, Gretch DR. JAMA. 2007 Feb 21;297(7):724-32.
• Screening for hepatitis C virus infection in adults: Recommendation statement
  US Preventive Services Task Force, Ann Intern Med. 2004 Mar 16;140(6):462-4.
• Screening for hepatitis C virus infection: A review of the evidence for the US Preventive Services Task Force
  Chou, R, et al. Ann Intern Med. 2004 Mar 16;140(6):465-79.
• Summaries for patients: Screening for hepatitis C virus infection: Recommendations from the US Preventive Service Task Force
  Ann Intern Med. 2004 Mar 16;140(6):I62.

Clinical Management

• Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial.
  Fried MW, Navarro VJ, Afdhal N, et al; Silymarin in NASH and C Hepatitis (SyNCH) Study Group. JAMA. 2012 Jul 18;308(3):274-82.
• Pegylated interferon-associated retinopathy is frequent in HCV patients with hypertension and justifies ophthalmologic screening.
  Vujosevic S, Tempesta D, Noventa F, et al. Hepatology. 2012 Feb 13. doi: 10.1002/hep.25654. [Epub ahead of print].
• Managing Hepatitis C in the VA Health Care System.
  Durfee JM, Czarnogorski M, Backus LI, et al. Fed Practitioner Supplement. August 2011; 28(3) (digital edition with audio clips).
• Outcomes of treatment for hepatitis C virus infection by primary care providers.
  Arora S, Thornton K, Murata G, et al. N Engl J Med. 2011 Jun 9;364(23):2199-207. Epub 2011 Jun 1.
  • Ensuring equal access to specialty care. [Editorial]
    Sequist TD. N Engl J Med. 2011 Jun 9;364(23):2258-9. Epub 2011 Jun 1.
• Clinical practice. Chronic hepatitis C infection.
  Rosen HR. N Engl J Med. 2011 Jun 23;364(25):2429-38.
• Significant Reductions in Drinking Following Brief Alcohol Treatment Provided in a Hepatitis C Clinic.
  Dieperink E, Ho SB, Heit S, Durfee JM, Thuras P, Willenbring ML. Psychosomatics. 2010 Mar;51(2):149-56.
• Diagnosis, management, and treatment of hepatitis C: an update.
  Ghany MG, Strader DB, Thomas DL, et al. Hepatology. 2009 Apr;49(4):1335-74.
• Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study.
  Uto H, Stuver SO, Hayashi K, et al. Hepatology. 2009 Apr 1;50(2):393-399.
• Liver biopsy.
  AASLD Position Paper; Rockey DC, Caldwell SH, Goodman ZD, et al. Hepatology. 2009 Mar;49(3):1017-44.
• Improving clinical quality and efficiency with simple practice adjustments.
  Pocha C. Current Clinical Practice. 2008 Dec; 2(3):1-6.
• Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study.
  Addolorato G, et al. Lancet. 2007 Dec 8;370(9603):1915-22.
• Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis (AASLD Practice Guidelines).
  Garcia-Tsao G, et al. Hepatology. 2007 Sep;46(3):922-38.
• Alcohol and hepatitis C mortality among males and females in the United States: a life table analysis.
  Chen CM, et al. Alcohol Clin Exp Res. 2007 Feb;31(2):285-92.
• Risks of a range of alcohol intake on hepatitis C-related fibrosis
  Monto A, et al. Hepatology. 2004 Mar;39(3):826-34.
• Prevalence and predictors of herbal medication use in veterans with chronic hepatitis C
  Siddiqui U, et al. J Clin Gastroenterol. 2004 Aug;38(7):605-10.
• Complementary and alternative therapies in the treatment of chronic hepatitis C: a systematic review
  Coon JT and Ernst E. J Hepatol. 2004 Mar;40(3):491-500.
• Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.
  Ferenci P, Scherzer TM, Kerschner H, et al. Gastroenterology. 2008 Nov;135(5):1561-7.

Treatment

• Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection.
  Lawitz E, Mangia A, et al. N Engl J Med. 2013 Apr 23. [Epub ahead of print].
• Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options.
  Jacobson IM, Gordon SC, et al. N Engl J Med. 2013 Apr 23. [Epub ahead of print].
• Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.
  Gane EJ et al. N Engl J Med. 2013 Jan 3; 368:34.
• Exploratory study of oral combination antiviral therapy for hepatitis.
  Poordad F. N Engl J Med. 2013 Jan 3; 368:45.
• Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study.
  Lo Re V 3rd, Teal V, Localio AR, et al. Ann Intern Med. 2011 Sep 20;155(6):353-60.
• Preliminary study of two antiviral agents for hepatitis C genotype 1.
  Lok AS, Gardiner DF, Lawitz E, et al. N Engl J Med. 2012 Jan 19;366(3):216-24.
• Escitalopram for the prevention of peginterferon-a2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.
  Schaefer M, Sarkar R, Knop V, et al. Ann Intern Med. 2012 Jul 17;157(2):94-103.
• Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection.
  Jacobson IM, McHutchison JG, Dusheiko G, et al. N Engl J Med. 2011 Jun 23;364(25):2405-16.
• Telaprevir for retreatment of HCV infection.
  Zeuzem S, Andreone P, Pol S, et al. N Engl J Med. 2011 Jun 23;364(25):2417-28.
• The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus Genotype 1 Infection, But With Issues Still Pending [Review Article]
  Pawlotsky JM. Gastroenterology. 2011 Mar;140(3):746-54.
• Boceprevir for untreated chronic HCV genotype 1 infection.
  Poordad F, McCone J Jr, Bacon BR, et al. N Engl J Med. 2011 Mar 31;364(13):1195-206.
• Boceprevir for previously treated chronic HCV genotype 1 infection.
  Bacon BR, Gordon SC, Lawitz E, et al. N Engl J Med. 2011 Mar 31;364(13):1207-17.
• Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.
  Marcellin P, Forns X, Goeser T, et al. Gastroenterology. 2011 Feb;140(2):459-468.
• Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
  Kwo PY, Lawitz EJ, McCone J, et al. Lancet. 2010 Aug 28;376(9742):705-16.
• Telaprevir for previously treated chronic HCV infection.
  McHutchison JG, Manns MP, Muir AJ, et al. N Engl J Med. 2010 Apr 8;362(14):1292-303.
• Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.
  Rumi MG, Aghemo A, Prati GM, et al. Gastroenterology. 2010 Jan;138(1):108-15.
• Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
  Ascione A, De Luca M, Tartaglione MT, et al. Gastroenterology. 2010 Jan;138(1):116-22.
• Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
  McHutchison JG, Lawitz EJ, Shiffman ML, et al. N Engl J Med. 2009 Aug 6;361(6):580-93.
• Effect of hepatitis C virus and its treatment on survival.
  Butt AA, Wang X, Moore CG. Hepatology. 2009 Jul 9;50(2):387-392.
• Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
  McHutchison JG, Everson GT, Gordon SC, et al. N Engl J Med. 2009 Apr 30;360(18):1827-38.
• Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
  Hészode C, Forestier N, Dusheiko G, et al. N Engl J Med. 2009 Apr 30;360(18):1839-50.
• Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients.
  George SL, Bacon BR, Brunt EM, et al. Hepatology. 2009 Mar;49(3):729-38.
• Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.
  Rodriguez-Torres M, et al; Latino Study Group. N Engl J Med. 2009 Jan 15;360(3):257-67.
• Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.
  Di Bisceglie AM, et al. N Engl J Med. 2008 Dec 4;359(23):2429-41.
• Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study.
  Rousseau CM, Ioannou GN, Todd-Stenberg JA, et al. Am J Public Health. 2008 May;98(5):846-52.
• Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
  Shiffman ML, et al. Gastroenterology. 2007 Jan;132(1):103-12.
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
  Fried MW, Shiffman ML, Reddy KR, et al. N Engl J Med. 2002 Sep 26;347(13):975-82.

HIV Coinfection

• The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection.
  Ioannou GN, Bryson CL, Weiss NS, et al. Hepatology. 2013 Jan;57(1):249-57.
• Management of chronic hepatitis C virus infection in HIV-infected patients.
  Pol S, Soriano V. Clin Infect Dis. 2008 Jul 1;47(1):94-101.
• HIV and Liver Disease Forum: Conference Proceedings [pdf]
  Kenneth E. Sherman, KE, et al. Hepatology. 2007 Jun;45(6):1566-77.
• Viral hepatitis in HIV infection.
  Koziel MJ, Peters MG. N Engl J Med. 2007 Apr 5;356(14):1445-54.
• Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
  Carrat F, Bani-Sadr F, Pol S, et al. JAMA. 2004 Dec 15;292(23):2839-48.
• Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.
  Laguno M, Murillas J, Blanco JL, et al. AIDS. 2004 Sep 3;18(13):F27-36.
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients
  Torriani FJ, et al. N Engl J Med. 2004 Jul 29;351(5):438-50.
• Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons
  Chung RT, et al. N Engl J Med. 2004 Jul 29;351(5):451-9.

Hepatitis C and Associated Diseases

• Screening for diabetes and prediabetes.
  Kenealy T, Elley CR, Arroll B. Lancet. 2007 Dec 8;370(9603):1888-9.
• Do high lipids help clearance of hepatitis C?
  Ryder S. Gut. 2007 Aug;56(8):1044-5.
• Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication.
  Huang JF, Dai CY, Hwang SJ, et al. Am J Gastroenterol. 2007 Jun;102(6):1237-43.

Hepatitis B

• Screening high risk individuals for hepatitis B: physician knowledge, attitudes, and beliefs.
  Foster T, Hon H, Kanwal F, et al. Dig Dis Sci. 2011 Dec;56(12):3471-87. Epub 2011 Oct 15.
• Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey.
  Ioannou GN. Ann Intern Med. 2011 Mar 1;154(5):319-28.
• Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection.
  Shamliyan TA, Johnson JR, Macdonald R, et al. J Gen Intern Med. 2011 Mar;26(3):326-39.
• Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment.
  Juday T, Tang H, Harris M, et al. J Gen Intern Med. 2011 Mar;26(3):239-44.
• Hepatitis B--more treatments, more testing, not enough data.
  Fox, RK. J Gen Intern Med. 2011 Mar;26(3):232-3.
• Chronic Hepatitis B: Update 2009 (AASLD Practice Guidelines).
  Lok, AS and McMahon, BJ. Hepatology. 2009 Sep;50(3):661-2.
• Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time.
  Tai DI, Lin SM, Sheen IS, et al. Hepatology. 2009 Feb; 49(6):1859-1867.
• National Institutes of Health Consensus Development Conference Statement: management of hepatitis B.
  Sorrell MF, Belongia EA, Costa J, et al. Ann Intern Med. 2009 Jan 20;150(2):104-10.
• Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference.
  Shamliyan TA, MacDonald R, Shaukat A, et al. Ann Intern Med. 2009 Jan 20;150(2):111-24. Review.
• Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008.
  Thompson ND, Perz JF, Moorman AC, Holmberg SD. Ann Intern Med. 2009 Jan 6;150(1):33-9. Review.

Cirrhosis

• Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
  Afdhal NH, Giannini EG, Tayyab G et al; ELEVATE Study Group. N Engl J Med. 2012 Aug 23;367(8):716-24.
• Does this patient with liver disease have cirrhosis?
  Udell JA, Wang CS, Tinmouth J et al. JAMA. 2012 Feb 22;307(8):832-42.
• Rifaximin treatment in hepatic encephalopathy
  Bass NM, Mullen KD, Sanyal A et al. N Engl J Med. 2010 Mar 25;362(12):1071-81.
• Management of varices and variceal hemorrhage in cirrhosis.
  Garcia-Tsao, G, and Bosch, J. N Engl J Med. 2010 Mar 4;362(9):823-32.
• The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club.
  Moore KP, Wong F, Gines P, et al. Hepatology. 2003;38:258-66.

Hepatocellular Carcinoma

• Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy.
  Lai CL, Yuen MF. Hepatology. 2013 Jan;57(1):399-408.
• Screening for liver cancer: the rush to judgment.
  Lederle FA, Pocha C. Ann Intern Med. 2012 Mar 6;156(5):387-9.
• Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a population-based cohort study, 1992-2007.
  Thein HH, Walter SR, Gidding HF, et al. J Viral Hepat. 2011 Jul;18(7):e232-41. doi: 10.1111/j.1365-2893.2011.01440.x. Epub 2011 Feb 17.
• Current Concepts: Hepatocellular Carcinoma
  El-Serag, HB. N Engl J Med 2011;365:1118-27.
• Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.
  Davila JA, Henderson L, Kramer JR, et al. Ann Intern Med. 2011 Jan 18;154(2):85-93.
• Hepatocellular Carcinoma in Veterans: Are We Prepared for an Epidemic?
  Pocha, C. Fed Practitioner. 2010 July; 27: Suppl(6).
• Managing Hepatocellular Carcinoma: The Nurse's Role
  Gholz, R and Engstrom, C. Fed Practitioner. 2010 Jan; 27: Suppl(1).
• Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C
  Report from the Institute of Medicine, Jan 11, 2010
• Managing Advanced Hepatocellular Carcinoma.
  Divekar R, Mehta P, El-Serag H, et al. Fed Pract. 2009 May;26(suppl 1):1-24B.
• Sorafenib in advanced hepatocellular carcinoma. Llovet JM, Ricci S, Mazzaferro V, et al. N Engl J Med. 2008 Jul 24;359(4):378-90.
• Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study.
  Ikeda K, et al. Ann Intern Med. 2007 May 1;146(9):649-56.
• Hepatocellular cancer: a guide for the internist.
  Parikh S, Hyman D. Am J Med. 2007 Mar;120(3):194-202. Review.
• Management of Hepatocellular Carcinoma. (AASLD Practice Guideline)
  Bruix J and Sherman M. Hepatology. 2005 Nov;42(5):1208-36.

Liver Transplant

• Summary report of a national conference: Evolving concepts in liver allocation in the MELD and PELD era
  Olthoff KM, et al. Liver Transpl. 2004 Oct;10(10 Suppl 2):A6-22.
• Comparative analysis of outcome following liver transplantation in US veterans
  Austin GL, et al. Am J Transplant 2004 May;4(5):788-95.
• Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C
  Wiesner RH, et al. Liver Transpl. 2003 Nov;9(11):S1-9.